MARKET

AMYT

AMYT

Amryt Pharma Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.01
-0.07
-0.54%
Opening 11:41 09/21 EDT
OPEN
12.00
PREV CLOSE
12.07
HIGH
12.29
LOW
12.00
VOLUME
2.18K
TURNOVER
--
52 WEEK HIGH
15.50
52 WEEK LOW
7.90
MARKET CAP
380.56M
P/E (TTM)
-14.3309
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
AMRYT PHARMA PLC(“Amryt” or the “Company”)Exercise of Warrants & Issue of Ordinary Shares and Total Voting RightsDUBLIN, Ireland, and Boston MA, September 21 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics
GlobeNewswire · 5h ago
AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103
AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103 DUBLIN, Ireland, and Boston MA, September 15 2020,  Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing
GlobeNewswire · 6d ago
Mid-Day Market Update: Dow Jumps Over 500 Points; Trillium Therapeutics Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 1.90% to 28,024.77 while the NASDAQ rose 2.69% to 11,139.51. The S&P also rose, gaining 2.18% to 3,404.35.
Benzinga · 09/09 16:04
Intra-Cellular Therapies, Trillium Therapeutics leads gainers, Co-Diagnostics, Applied Genetic Technologies among losers
Gainers: Intra-Cellular Therapies (ITCI) +65%, Trillium Therapeutics (TRIL) +36%, Amryt Pharma (AMYT) +25%, BeyondSpring (BYSI) +18%, XTL Biopharmaceuticals (XTLB) +17%.Losers: Co-Diagnostics (CODX) -17%, Applied Genetic Technologies (AGTC) -16%, SCWorx (WORX) -10%, Innate Pharma (IPHA) -7%, PolarityTE (PTE) -5%.
Seekingalpha · 09/09 15:07
POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT ANNOUNCES POSITIVE TOP LINE RESULTS FROM PIVOTAL PHASE 3 “EASE” TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA\- Primary endpoint met with statistical significance (p-value = 0.013)\- FILSUVEZ® demonstrated a good safety profile\- EASE is the first
GlobeNewswire · 09/09 12:01
Amryt Pharma reports Q2 results
Amryt Pharma (NASDAQ:AMYT): Q2 GAAP EPS of -$0.12. Revenue of $46.19M (+893.3% Y/Y) Press Release
seekingalpha · 08/06 16:11
AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020
AMRYT ANNOUNCES Q2 2020 RESULTS AND ISSUES POSITIVE REVENUE GUIDANCE FOR FY 2020New revenue guidance of $170M - $175M in 2020Conference call and webcast today 0830 ET / 1330 BSTDUBLIN, Ireland, and Boston MA, August 6, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Eur
GlobeNewswire · 08/06 11:01
These 2 Small-Cap Stocks Could See 50%-Plus Gains, Says Canaccord
In this time of pandemic, stock markets have mostly been – rising. Yes, we had a crash in February/March, part of that initial ‘panic mode’ when Federal, state, and local governments shut down economic activity and ordered social lockdown policies, but that tu
TipRanks · 08/03 20:42
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMYT stock price target is 42.50 with a high estimate of 45.00 and a low estimate of 40.00.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
No Data

Analyst Price Target

The average AMYT stock price target is 42.50 with a high estimate of 45.00 and a low estimate of 40.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AMYT
Amryt Pharma Holdings Limited, formerly Amryt Pharma plc, is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. Its products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. It holds a license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Amryt Pharma Holdings Ltd stock information, including NASDAQ:AMYT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMYT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMYT stock methods without spending real money on the virtual paper trading platform.